BIO-Europe 2018
BIO-Europe 2018 Access Management Presentation
BIO-Europe 2018 Access Management Presentation
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
Watch the interview on La Bourse et la Vie.com (in French)
Watch CEO Judith Greciet’s presentation (French only) https://vimeo.com/304376654
Advancing innovation towards breakthrough cancer therapies Paris, April 9, 2018 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ […]
First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted […]
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, […]
Onxeo Announces its Financial Agenda for 2018 Paris (France), January 23, 2018 – 5:45 pm CET – Onxeo S.A. […]
39th EORTC-PAMM Winter Meeting The PAMM Meeting is the ideal setting to discuss how new treatment strategies can be […]
Conference Call – Interim results of DRIIV-1 study Access to the replay of the conference call Access to the […]
Watch video on Edison TV
Transaction reinforces Company’s cash position and proceeds will be fully allocated to the advancement of Onxeo’s pipeline, including its […]
European Large & MidCap Event 2018 Access Management Presentation
Les Echos/Investir – BoursoCap Access Management Presentation (French only) View CEO Judith Greciet’s presentation on Vimeo (French only)
Approval of all ordinary resolutions Renewal of the terms of office of Mr. Thomas Hofstaetter Notice of a new Extraordinary […]
Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with […]
Paris (France), March 14th, 2018 – 8:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]
Paris (France), January 23, 2018 – 09:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), (“Onxeo” or […]
Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031 Composition of matter patent […]
Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]
Development of lead product candidate, AsiDNA™, for the treatment of advanced solid tumors, progressing according to plan DRIIV phase I […]
Paris (France), May 23, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]
Cash for Operations Extended to Q3 2020 Paris (France), June 15, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext […]
AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model […]
Clinical development of Onxeo’s lead product candidate AsiDNA™ progressing to plan Preliminary safety and activity results of DRIIV-1 study are […]
Paris (France), September 13, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), a […]
Paris, October 3, 2018 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology […]
Paris, October 18, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology […]
AsiDNA™ clinical development progressing to plan First safety and activity results of the phase I DRIIV-1 study expected in Q4 […]
Paris (France), December 13, 2018 – 7 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology […]
Combination patent to be granted in Europe until 2036 Paris (France), December 18, 2018 – 8.30 pm CET – […]
Paris (France), December 20, 2018 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage […]